Document is current

Any future updates will be listed below

PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs in Japan; durvalumab, cemiplimab, zongertinib, and taletrectinib for lung cancer, pirtobrutinib and atezolizumab for lymphoma, durvalumab for bladder cancer, panitumumab plus sotorasib for colorectal cancer, and vorasidenib for glioma

Crossref DOI link: https://doi.org/10.1007/s10147-025-02901-3

Published Online: 2025-10-25

Published Print: 2025-12

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark